IFNA1 and COVID-19: Recent evidence suggests COVID-19 immunopathogenesis as a multi-step process that closely correlated with disease severity and prognosis.29 To examine whether this GC–IFN synergy is timing-dependent, we defined early GC therapy as initiation of GC therapy within 5 days after admission, which overlapped with early IFN therapy, and stratified GC users according to this criterion.